Aminoglycosides are a class of antibiotics that kill bacteria by interfering with their ability to build proteins correctly. First discovered in the 1940s with streptomycin, they remain some of the most potent weapons against serious infections caused by gram-negative bacteria, and they show up in hospital settings far more than most people realize. Their effectiveness comes with a well-known trade-off, though: they can damage the kidneys and the inner ear, which has shaped decades of research into how to use them more safely and who should avoid them altogether.
Origins and the Drugs in the Class
The story of aminoglycosides begins with Selman Waksman, who won the 1952 Nobel Prize for his systematic screening of soil-dwelling microorganisms called actinomycetes. His lab isolated streptomycin from the genus Streptomyces, and the drug became the first effective treatment for tuberculosis. Waksman’s use of submerged culture techniques allowed large-scale production, which in turn enabled rapid animal testing and human clinical trials against Mycobacterium tuberculosis.1PubMed Central. Selman A. Waksman, winner of the 1952 Nobel Prize for physiology or medicine
Since streptomycin, the class has expanded to include gentamicin, tobramycin, amikacin, neomycin, kanamycin, and several others. What ties them together is a shared chemical backbone: they all contain amino-modified sugars linked to a central ring structure. Each member differs slightly in its sugar attachments, which matters because those differences determine which bacteria they work against and which resistance enzymes can deactivate them.
How They Kill Bacteria
Aminoglycosides work by latching onto a specific part of the bacterial ribosome, the molecular machine that reads genetic instructions and assembles proteins. Specifically, they bind to a region called the A-site on the smaller subunit of the ribosome (the 30S subunit), which is where incoming building blocks are matched to the genetic code.2Chemistry & Biology. Specific Binding of Aminoglycosides to the A-Site of Decoding Region 16S RNA Once bound, the drug distorts the shape of this region enough that the ribosome starts making mistakes: it misreads the genetic code, inserts the wrong building blocks into proteins, and stalls partway through the assembly process.3PubMed. Binding of neomycin-class aminoglycoside antibiotics to the A-site of 16 S rRNA
This misreading is the key to why aminoglycosides are bactericidal rather than merely growth-inhibiting. The scrambled proteins produced under drug pressure include membrane proteins. When these defective proteins get inserted into the bacterial cell membrane, they create holes and disrupt the membrane’s integrity.4PubMed. The bactericidal action of streptomycin: membrane permeabilization caused by the insertion of mistranslated proteins into the cytoplasmic membrane of Escherichia coli and subsequent caging of the antibiotic inside the cells due to degradation of these proteins The damaged membrane then lets even more drug molecules flood in, creating a self-amplifying cycle that overwhelms the cell. Research has shown this membrane damage also activates stress-response systems inside the bacterium, compounding the lethal effect.5PubMed Central. Mistranslation of membrane proteins and two-component system activation trigger aminoglycoside-mediated oxidative stress and cell death
Getting inside the bacterium in the first place is a multi-step process. Aminoglycosides carry a positive charge, which helps them cross the negatively charged outer membrane of gram-negative bacteria. But deeper entry into the cell depends on the bacterium’s own energy-producing machinery. Studies have shown that both an electrical charge across the cell membrane and active electron transport are needed for effective drug uptake. Blocking the electron transport chain with poisons like cyanide prevents the drug from getting in, even when the membrane voltage is adequate on its own.6PubMed Central. Roles of ribosomal binding, membrane potential, and electron transport in bacterial uptake of streptomycin and gentamicin This energy dependence explains why aminoglycosides work poorly against bacteria growing without oxygen, since anaerobic conditions produce much less membrane voltage.
What They Are Used For
Despite the arrival of many newer antibiotics over the decades, aminoglycosides have not been retired. They remain a front-line choice for serious gram-negative infections, particularly in hospitals where organisms like Pseudomonas aeruginosa and resistant Enterobacteriaceae are common threats. They also play important roles in treating enterococcal infections and mycobacterial diseases, including tuberculosis. Amikacin stands out for its broader coverage: it works against many gentamicin-resistant gram-negative bacteria and is used against infections caused by Nocardia and nontuberculous mycobacteria.7PubMed. The aminoglycosides
In clinical practice, aminoglycosides are frequently paired with other antibiotics, particularly beta-lactams, with the idea that the combination kills bacteria faster. This synergy is real in the lab, but in at least one important setting, the evidence for clinical benefit is less clear-cut. A meta-analysis of combination therapy for bacterial endocarditis found no statistically significant difference between beta-lactam monotherapy and beta-lactam plus aminoglycoside in terms of mortality, treatment success, or relapse. What the combination did produce was more kidney toxicity.8Journal of Antimicrobial Chemotherapy. The role of aminoglycosides in combination with a β-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials This finding has pushed some clinicians to think more carefully about when the combination is truly necessary versus when it just adds risk.
Once-Daily Dosing and Why It Works
One of the more interesting pharmacological features of aminoglycosides is that they kill bacteria faster at higher concentrations. Unlike some antibiotics that just need to stay above a minimum level in the blood, aminoglycosides’ germ-killing power scales up with peak drug levels. They also produce a prolonged suppressive effect even after the drug concentration drops below the level needed to kill outright, a phenomenon called the post-antibiotic effect.9PubMed. Pharmacokinetic contributions to postantibiotic effects. Focus on aminoglycosides This concentration-dependent killing and the post-antibiotic effect were demonstrated across the commonly used members of the class, including amikacin, gentamicin, and tobramycin.10Journal of Antimicrobial Chemotherapy. Postantibiotic effect in Pseudomonas aeruginosa following single and multiple aminoglycoside exposures in vitro
These properties opened the door to a dosing revolution. Instead of splitting the daily dose into two or three smaller infusions, clinicians began giving the entire dose once a day. The logic is that one big peak kills bacteria effectively and the long drug-free trough period lets kidney cells recover. Multiple meta-analyses have confirmed that once-daily dosing works at least as well as traditional dosing while carrying a lower risk of kidney damage.11BMJ. Single or multiple daily doses of aminoglycosides: a meta-analysis One meta-analysis in people with healthy immune systems found equivalent rates of bacterial cure and a trend toward reduced mortality with once-daily regimens, along with practical advantages like easier scheduling and less nursing time.12PubMed. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis
A prospective study put more specific numbers to the kidney benefit: roughly 15% of patients on twice-daily aminoglycosides developed nephrotoxicity, compared with none of those receiving the drug once daily. The schedule of dosing, the total daily drug exposure, and whether vancomycin was given at the same time all independently predicted kidney damage.13PubMed Central. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity Once-daily dosing is now standard practice in most hospitals, though clinicians still monitor blood levels to stay in the safe range.
Kidney Damage and How It Happens
Nephrotoxicity is the most common serious side effect of aminoglycosides. The drugs accumulate in cells lining the kidney tubules, the tiny tubes that filter and reclaim useful molecules from urine. A receptor protein called megalin, found on the surface of these cells, actively grabs aminoglycoside molecules from the fluid passing through and pulls them inside.14PubMed Central. Gentamicin binds to the megalin receptor as a competitive inhibitor using the common ligand binding motif of complement type repeats Once inside, the drugs accumulate in cellular compartments and eventually damage the cell. The kidney injury is usually reversible if the drug is stopped in time, because tubular cells can regenerate. But prolonged courses or high cumulative doses raise the stakes considerably.
Practical risk management revolves around keeping courses as short as possible, using once-daily dosing, avoiding other kidney-toxic drugs at the same time (vancomycin being a common offender), and monitoring blood levels. The goal is to hit a peak concentration high enough to kill bacteria while ensuring the trough level drops low enough for kidney cells to clear the drug before the next dose.
Hearing Loss and Genetic Vulnerability
The other feared toxicity is damage to the inner ear, which can cause permanent hearing loss, balance problems, or both. Aminoglycosides are selectively toxic to sensory hair cells, the delicate cells in the cochlea that convert sound vibrations into electrical signals for the brain. Once these cells die, they do not regenerate in humans. The drugs appear to enter hair cells partly through the same channels the cells use to detect mechanical vibration, and once inside, they target mitochondrial ribosomes, which structurally resemble the bacterial ribosomes the drugs were designed to attack.15PubMed Central. Towards the Prevention of Aminoglycoside-Related Hearing Loss
This mitochondrial connection is why certain people face dramatically higher risk. Specific mutations in mitochondrial DNA, particularly in the gene for 12S ribosomal RNA, make human mitochondrial ribosomes look even more like bacterial ribosomes. The two best-studied mutations are m.1555A>G and m.1494C>T. People carrying either of these changes can develop severe, irreversible hearing loss from even a single standard dose of an aminoglycoside.16PubMed Central. Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity These mutations are inherited maternally and affect all mitochondria throughout the body, but the inner ear is uniquely vulnerable because of hair cells’ dependence on mitochondrial function and their inability to regenerate. Community screening has identified carriers even among people with no prior hearing complaints, though these individuals remain at risk of progressive hearing loss if they ever receive an aminoglycoside.17Human Genome Variation. Prevalence of the mitochondrial 1555 A>G and 1494 C>T mutations in a community-dwelling population in Japan
The prevalence of these mutations varies by population, but in general, somewhere between one in several hundred to one in a few thousand people carry one. Genetic testing before aminoglycoside use is increasingly discussed, though it is far from routine everywhere. In clinical settings where aminoglycosides are used in neonates, for instance, rapid point-of-care genetic tests are being piloted to flag at-risk infants before their first dose.
Neuromuscular Effects
A less commonly discussed but clinically significant side effect is neuromuscular blockade. Aminoglycosides can interfere with nerve-to-muscle signaling by antagonizing calcium at the nerve terminal, reducing the release of the neurotransmitter that tells muscles to contract. Among the commonly used agents, gentamicin is the most potent in this regard.18PubMed. Neuromuscular blocking activity of aminoglycoside antibiotics This effect is usually subclinical, but it becomes dangerous when aminoglycosides are given to patients who are already receiving muscle-relaxant drugs during surgery or to people with neuromuscular conditions like myasthenia gravis. The combination can cause prolonged paralysis of respiratory muscles. Calcium administration can reverse this blockade, and the effect varies depending on the muscle group: peripheral limb muscles tend to be more susceptible than the diaphragm.19PubMed. Neuromuscular blocking effects of the aminoglycoside antibiotics arbekacin, astromicin, isepamicin and netilmicin on the diaphragm and limb muscles in the rabbit
How Bacteria Resist Aminoglycosides
Resistance to aminoglycosides is a growing clinical problem, and bacteria have evolved several distinct strategies to survive exposure. The most common mechanism involves enzymes that chemically modify the drug molecule, attaching small chemical groups that change its shape enough that it no longer fits snugly into the ribosomal target. Three enzyme families do this work: acetyltransferases, phosphotransferases, and nucleotidyltransferases, each attacking different spots on the drug’s sugar or amino groups.20PubMed Central. Aminoglycoside modifying enzymes Bacteria sometimes carry multiple modifying enzymes, and research has shown that these can act in sequence, with one enzyme modifying the drug and a second adding yet another modification for more robust inactivation.21PubMed Central. Effects of altering aminoglycoside structures on bacterial resistance enzyme activities
A more alarming resistance strategy involves enzymes that modify the ribosome itself rather than the drug. Acquired 16S rRNA methyltransferases, such as ArmA and NpmA, add chemical tags directly to the ribosomal target site, blocking all clinically useful aminoglycosides from binding.22PubMed Central. Aminoglycoside resistance 16S rRNA methyltransferases block endogenous methylation, affect translation efficiency and fitness of the host Until recently, NpmA had been the only known acquired enzyme capable of conferring resistance to all aminoglycosides, but researchers have now characterized NpmB1, a related enzyme identified in Escherichia coli from the United Kingdom with only 40% sequence similarity to NpmA, suggesting this resistance strategy is diversifying.23PubMed Central. Functional and Structural Characterization of Acquired 16S rRNA Methyltransferase NpmB1 Conferring Pan-Aminoglycoside Resistance Even more concerning, the npmA gene has now been found on mobile genetic elements in gram-positive bacteria like Enterococcus faecium, meaning it can spread between unrelated species of bacteria.24PubMed Central. Global dissemination of npmA mediated pan-aminoglycoside resistance via a mobile genetic element in Gram-positive bacteria
Plazomicin and the Push for Newer Aminoglycosides
The growing resistance problem prompted efforts to design aminoglycosides that can dodge the most common modifying enzymes. Plazomicin, approved in the United States in 2018, was built by chemically modifying sisomicin with structural additions at specific positions that block the enzymes from attaching their inactivating groups.25PubMed Central. Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes The result is enhanced activity against resistant Enterobacteriaceae, including many strains that shrug off gentamicin and tobramycin.26PubMed. Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections Plazomicin still cannot overcome the ribosomal methyltransferases, however, so it is not a universal fix.
A separate line of research is pursuing “designer aminoglycosides” that retain antibacterial activity while reducing toxicity to human cells. One approach modifies the drug’s ability to enter inner ear hair cells through the mechanotransducer channel. Researchers have produced modified versions of sisomicin that carry less positive charge and are therefore less likely to pass through the channel into hair cells. In laboratory studies, these designer compounds blocked hair cell entry while preserving antibacterial effect against test organisms.27JCI Insight. Designer aminoglycosides prevent cochlear hair cell loss and hearing loss This work is still preclinical, but it represents a conceptually elegant path: tweaking the drug so it fits the bacterial target just fine but no longer fits the door into human sensory cells.
Protecting Against Hearing and Balance Damage
While waiting for inherently safer drugs, researchers have explored co-administering protective agents alongside aminoglycosides. The underlying rationale is that much of the inner ear damage involves oxidative stress, driven partly by a reaction between the aminoglycoside molecule and iron inside cells. Animal studies have shown that co-injecting iron chelators and free-radical scavengers alongside aminoglycosides can significantly reduce hearing loss without affecting the drug’s blood levels or its ability to kill bacteria.28PubMed. Iron chelators protect from aminoglycoside-induced cochleo- and vestibulo-toxicity Among a panel of antioxidants tested against gentamicin-induced damage in guinea pigs, D-methionine emerged as a standout protectant, significantly reducing hearing threshold shifts.29Hearing Research. Antioxidants attenuate gentamicin-induced free radical formation in vitro and ototoxicity in vivo: D-methionine is a potential protectant None of these protective strategies has become standard clinical practice yet, partly because human trials are difficult to design and fund for a co-therapy that prevents damage from another drug. But for patients who absolutely need a prolonged aminoglycoside course, such as in multidrug-resistant tuberculosis, the concept remains actively studied.
Aminoglycosides Beyond Infection
An unexpected second life for aminoglycosides has emerged from the very property that makes them dangerous antibiotics: their ability to cause the ribosome to misread genetic code. In human cells, some genetic diseases are caused by “nonsense” mutations, single-letter changes in DNA that create a premature stop signal in the middle of a gene. The cell reads the instruction, hits the stop signal too early, and produces a truncated, nonfunctional protein. Aminoglycosides can sometimes force the ribosome to skip over these premature stop signals and produce a full-length protein instead.30PubMed Central. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development
This “readthrough” effect has been explored most extensively in Duchenne muscular dystrophy, where roughly 10-15% of cases are caused by nonsense mutations. Gentamicin has been tested as a readthrough agent in this context, with early studies showing that it can restore partial production of the missing protein, dystrophin.31PubMed Central. Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy The practical problem is obvious: the doses needed to push enough readthrough carry all the toxicity risks described above, especially for the chronic administration a genetic disease would require. This has driven the search for non-aminoglycoside readthrough drugs and for modified aminoglycosides that promote readthrough with less toxicity. The concept extends well beyond muscular dystrophy to any genetic disease caused by a premature stop codon, including certain forms of cystic fibrosis and some cancer predisposition syndromes.
Monitoring Drug Levels in Practice
Because the window between an effective dose and a toxic one is narrow, therapeutic drug monitoring is considered essential for aminoglycoside therapy. Clinicians draw blood samples to measure peak levels (to confirm the drug reached a high enough concentration to kill bacteria) and trough levels (to confirm it has cleared enough to spare the kidneys). In once-daily regimens, a single level drawn several hours after the dose is often used instead, plugged into a nomogram to predict whether the drug will clear adequately before the next dose. Despite the recognized importance of this monitoring, implementation varies widely. A survey of Japanese university hospitals found that routine therapeutic drug monitoring for aminoglycosides was not consistently available, highlighting a gap between guidelines and real-world practice.32PubMed Central. Therapeutic Drug Monitoring for Aminoglycosides: Not Yet Readily Available in Japanese University Hospitals In resource-limited settings around the world, the situation is often worse, meaning patients may receive aminoglycosides with less toxicity surveillance than the drugs demand.
Variability in drug clearance from person to person makes monitoring especially important. Kidney function, body weight, fluid status, age, and critical illness all shift how quickly a patient eliminates an aminoglycoside. A dose that is perfectly safe in one patient may accumulate dangerously in another. The interplay between these variables is one reason aminoglycosides, despite their age and familiarity, still require a level of clinical attention that newer antibiotics with wider safety margins do not.